Last reviewed · How we verify

OnabotulinumtoxinA (BOTOX®) — Competitive Intelligence Brief

OnabotulinumtoxinA (BOTOX®) (OnabotulinumtoxinA (BOTOX®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Aesthetics.

phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Dermatology, Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

OnabotulinumtoxinA (BOTOX®) (OnabotulinumtoxinA (BOTOX®)) — Naval Medical Center Camp Lejeune. OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OnabotulinumtoxinA (BOTOX®) TARGET OnabotulinumtoxinA (BOTOX®) Naval Medical Center Camp Lejeune phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox 100 UNT Injection Botox 100 UNT Injection Brigitte Schürch marketed Botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA (ONA) OnabotulinumtoxinA (ONA) Hexsel Dermatology Clinic marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
NAFT600 (adult) NAFT600 (adult) Merz North America, Inc. marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)
Onabotulinumtoxin A (BoNT) Onabotulinumtoxin A (BoNT) Edgar LeClaire, MD marketed Neurotoxin; botulinum toxin serotype A SNAP-25 (synaptosome-associated protein of 25 kDa)
NAFT500 (adult) NAFT500 (adult) Merz North America, Inc. marketed Botulinum toxin type A SNARE complex (acetylcholine release machinery)
Intradetrusor Botox Injections Intradetrusor Botox Injections The Methodist Hospital Research Institute marketed Neurotoxin; botulinum toxin type A SNARE complex (synaptosomal-associated protein); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

  1. Galderma R&D · 2 drugs in this class
  2. Hexsel Dermatology Clinic · 2 drugs in this class
  3. Seoul National University Hospital · 2 drugs in this class
  4. University of Utah · 2 drugs in this class
  5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
  6. EuBiologics Co.,Ltd · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Beth Israel Deaconess Medical Center · 1 drug in this class
  10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OnabotulinumtoxinA (BOTOX®) — Competitive Intelligence Brief. https://druglandscape.com/ci/onabotulinumtoxina-botox. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: